Eyestem key facts
as of Oct 2026- Developer of scalable cell replacement therapies designed to treat incurable diseases.
- Eyestem is valued at approximately $46.9M as of Oct 2026 (last reported valuation).
- It has raised $20.0M; the latest was Later Stage VC ($10.0M) in Aug 2025.
- Notable investors include BIRAC, Alkem Laboratories, Anurag Bagaria, Biological E, Centre for Cellular And Molecular Platforms — 23 tracked in total.
- Status: Privately Held (backing).
Eyestem's last reported valuation, Jul 2022. Nothing priced has surfaced since.
- ·The complete investor list: 23 names
- ·Watch Eyestem: the Monday email on marks, rounds and moves
Eyestem funding rounds
No funding rounds for Eyestem are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Eyestem
23+Eyestem valuation
Eyestem's last reported valuation was $46.9 million in Jul 2022. No priced round, secondary trade or fund mark has surfaced since.
Eyestem investors
23 investors are on record for Eyestem, including BIRAC, Alkem Laboratories, Anurag Bagaria and Biological E.
About Eyestem
Developer of scalable cell replacement therapies designed to treat incurable diseases. The company's platform aims to replace damaged photoreceptor cells in the eye with healthy, transplantable cells derived from induced pluripotent stem cells to restore vision in patients with conditions like dry age-related macular degeneration, enabling healthcare professionals to offer treatments to patients.
- Sector
- Healthcare
- HQ
- Bengaluru, India
- Founded
- 2015
- Employees
- 10
- Website
- eyestem.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.